Abcuro Archives - intelligence360

Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis

February 19, 2025 Craig Etkin

February 12, 2025 07:00 AM Eastern Standard Time NEWTON, Mass.–(BUSINESS WIRE)–Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced…

Abcuro has filed a notice of an exempt offering of securities to raise $199,522,751.00 in New Equity Investment.

September 12, 2023 Craig Etkin

According to filings with the U.S. Securities and Exchange Commission, Abcuro is raising $199,522,751.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, John Martin played a key role in…

Newton Massachusetts based Abcuro is raising $20,000,000.00 in New Equity Investment.

July 17, 2020 Craig Etkin

Newton, MA – According to filings with the U.S. Securities and Exchange Commission, Abcuro is raising $20,000,000.00 in new funding. Sources indicate as part of senior management President, Stefano Gulla played a key role in…

intelligence360

The Intelligent News Source

Tag: Abcuro